Michael Garkavij

960 total citations
23 papers, 727 citations indexed

About

Michael Garkavij is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael Garkavij has authored 23 papers receiving a total of 727 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Radiology, Nuclear Medicine and Imaging, 8 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Michael Garkavij's work include Radiopharmaceutical Chemistry and Applications (18 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and Lymphoma Diagnosis and Treatment (4 papers). Michael Garkavij is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (18 papers), Monoclonal and Polyclonal Antibodies Research (15 papers) and Lymphoma Diagnosis and Treatment (4 papers). Michael Garkavij collaborates with scholars based in Sweden, Norway and Germany. Michael Garkavij's co-authors include Jan Tennvall, Sven‐Erik Strand, Tomas Ohlsson, Michael Ljungberg, Katarina Sjögreen Gleisner, Karin Wingårdh, Lars Franzén, Dag Clement Johannessen, Johan Harmenberg and K. Pigott and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Michael Garkavij

23 papers receiving 708 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Garkavij Sweden	10	546	351	314	95	79	23	727
Sarah M. Schwarzenböck Germany	17	473 0.9×	411 1.2×	215 0.7×	88 0.9×	36 0.5×	42	771
Thomas K. Rhee United States	13	370 0.7×	203 0.6×	197 0.6×	261 2.7×	105 1.3×	18	877
Berlinda J. de Wit–van der Veen Netherlands	16	420 0.8×	183 0.5×	361 1.1×	186 2.0×	100 1.3×	50	779
Gian Carlo Montini Italy	13	414 0.8×	349 1.0×	356 1.1×	285 3.0×	213 2.7×	20	961
Jean‐Philippe Vuillez France	15	526 1.0×	142 0.4×	210 0.7×	126 1.3×	50 0.6×	39	907
Seval Beykan Germany	9	627 1.1×	507 1.4×	327 1.0×	126 1.3×	70 0.9×	13	843
S. Asbell United States	3	297 0.5×	505 1.4×	145 0.5×	253 2.7×	93 1.2×	8	1.1k
Nicolas Chouin France	18	783 1.4×	387 1.1×	213 0.7×	70 0.7×	41 0.5×	37	944
R. Thödtmann Germany	9	496 0.9×	392 1.1×	221 0.7×	29 0.3×	57 0.7×	11	904
Paul E. Borchardt United States	10	623 1.1×	238 0.7×	187 0.6×	39 0.4×	30 0.4×	17	812

Countries citing papers authored by Michael Garkavij

Since Specialization

Citations

This map shows the geographic impact of Michael Garkavij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Garkavij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Garkavij more than expected).

Fields of papers citing papers by Michael Garkavij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Garkavij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Garkavij. The network helps show where Michael Garkavij may publish in the future.

Co-authorship network of co-authors of Michael Garkavij

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Garkavij. A scholar is included among the top collaborators of Michael Garkavij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Garkavij. Michael Garkavij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garkavij, Michael, Katarina Sjögreen Gleisner, Michael Ljungberg, et al.. (2010). ¹⁷⁷Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer. 116(S4). 1084–1092. 158 indexed citations

Nilsson, Rune, Michael Garkavij, Ola Lindén, et al.. (2010). Extracorporeal techniques for improving radioimmunotherapy of disseminated malignant tumors. Lund University Publications (Lund University). 1 indexed citations

Toporski, Jacek, Michael Garkavij, Jan Tennvall, et al.. (2009). High-Dose Iodine-131-Metaiodobenzylguanidine with Haploidentical Stem Cell Transplantation and Posttransplant Immunotherapy in Children with Relapsed/Refractory Neuroblastoma. Biology of Blood and Marrow Transplantation. 15(9). 1077–1085. 32 indexed citations

Nilsson, Sten, Lars Franzén, Christopher Parker, et al.. (2007). Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The Lancet Oncology. 8(7). 587–594. 354 indexed citations

Lindén, Ola, Jan Kurkus, Michael Garkavij, et al.. (2005). A Novel Platform for Radioimmunotherapy: Extracorporeal Depletion of Biotinylated and ⁹⁰ Y-Labeled Rituximab in Patients with Refractory B-Cell Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 20(4). 457–466. 28 indexed citations

Lindén, O., Jan Kurkus, Michael Garkavij, et al.. (2004). A novel platform for radioimmunotherapy. Extracorporeal depletion of biotinylated and ⁹⁰Y-labeled anti-CD20 in patients with refractory B-cell lymphoma. Journal of Clinical Oncology. 22(14_suppl). 6576–6576. 3 indexed citations

Wang, Zhong-Min, et al.. (2003). Biotinylation, Pharmacokinetics, and Extracorporeal Adsorption of Humanized MAb ¹¹¹ In-MN14 Using an Avidin-Affinity Column in Rats. Cancer Biotherapy and Radiopharmaceuticals. 18(3). 365–375. 4 indexed citations

Wang, Zhongmin, et al.. (2002). Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFG1-biotin. Cancer. 94(S4). 1287–1292. 6 indexed citations

Tennvall, Jan, Per‐Anders Abrahamsson, Göran Ahlgren, et al.. (2000). Palliative Radiation with a Radiolabeled Diphosphonate (Rhenium-186 Etidronate) in Patients with Hormone-Refractory Disseminated Prostate Carcinoma. Scandinavian Journal of Urology and Nephrology. 34(3). 188–193. 8 indexed citations

10.

Tennvall, Jan, Michael Garkavij, Jianqing Chen, Hans Sjögren, & Sven‐Erik Strand. (1997). Improving tumor‐to‐normal‐tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin‐biotin concept. Cancer. 80(S12). 2411–2418. 1 indexed citations

11.

Tennvall, Jan, Michael Garkavij, Jianqing Chen, Hans Sjögren, & Sven‐Erik Strand. (1997). Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept. Cancer. 80(S12). 2411–2418. 12 indexed citations

12.

Tennvall, Jan, Michael Garkavij, Jianqing Chen, Hans Sjögren, & Sven‐Erik Strand. (1997). Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.. PubMed. 80(12 Suppl). 2411–8. 13 indexed citations

13.

Garkavij, Michael, et al.. (1996). Extracorporeal Immunoadsorption from Whole Blood Based on the Avidin-Biotin Concept: Evaluation of a new method. Acta Oncologica. 35(3). 309–312. 11 indexed citations

14.

Chen, Jianing, Sven‐Erik Strand, Mats Isaksson, et al.. (1996). Biodistribution and pharmacokinetics of 125I/131I pair-labelled biotinylated chimeric BR96 in colon carcinoma isografted rats. Lund University Publications (Lund University). 2(4). 204–214. 5 indexed citations

15.

Garkavij, Michael, Sven‐Erik Strand, Hans Sjögren, et al.. (1995). 134 Enhanced tumor radioimmunotargeting of chimeric 125I-BR96-biotin in a syngeneic rat tumor model using whole blood extracorporeal immunoadsorption (ECIA). European Journal of Cancer. 31. S31–S31. 2 indexed citations

16.

Tennvall, Jan, et al.. (1994). ENHANCED RADIOIMMUNOTARGETING OF 125I-L6-BIOTIN MAb BY COMBINING PRELOAD OF COLD L6 MAB AND SUBSEQUENT IMMUNOADSORPTION ( ECIA ). Journal of Immunotherapy. 16(2). 158–158. 2 indexed citations

17.

Strand, Sven‐Erik, Kristina Norrgren, Michael Garkavij, et al.. (1994). A general extracorporeal immunoadsorption method to increase tumor-to-tissue ratio. Cancer. 73(S3). 1033–1037. 7 indexed citations

18.

Strand, Sven‐Erik, Michael Ljungberg, Jan Tennvall, Kristina Norrgren, & Michael Garkavij. (1994). Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption. Medical & Biological Engineering & Computing. 32(5). 551–561. 9 indexed citations

19.

Norrgren, Kristina, Michael Garkavij, Rune Nilsson, et al.. (1994). Extracorporeal immunoadsorption of 125I-labeled monoclonal antibody L6.. Lund University Publications (Lund University). 7(1). 29–42. 2 indexed citations

20.

Garkavij, Michael, Jan Tennvall, Sven‐Erik Strand, et al.. (1993). Improving Radioimmonotargeting of Tumors: Variation in the Amount of L6 Mab Administered, Combined with an Immunoadsorption System (Ecia). Acta Oncologica. 32(7-8). 853–859. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact